# 2025年12月4日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 术中驱动压引导的高呼气末正压与标准低呼气末正压对术后肺部并发症的影响

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41334859](https://pubmed.ncbi.nlm.nih.gov/41334859)
**期刊：** JAMA
**PMID：** 41334859
**DOI：** 10.1001/jama.2025.23373

### 第一部分 原文与翻译

**英文原标题：** Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications.

**英文摘要原文：**
IMPORTANCE: The effect of individualized high positive end-expiratory pressure (PEEP) and recruitment maneuvers, targeting a low driving pressure, on clinical outcomes in patients undergoing open abdominal surgery is uncertain.

OBJECTIVE: To compare driving pressure-guided high PEEP and recruitment maneuvers with standard low PEEP without recruitment maneuvers with respect to postoperative pulmonary complications.

DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial of 1435 adults at increased risk for postoperative pulmonary complications who were scheduled for open abdominal surgery. The trial was conducted at 29 sites in 5 countries across Europe from April 2019 to December 2024; final follow-up was in March 2025. Statistical analysis was conducted in May 2025.

INTERVENTION: Patients were randomized to undergo intraoperative ventilation with driving pressure-guided high PEEP and recruitment maneuvers (n = 718) or to intraoperative ventilation with standard low PEEP (n = 717). All patients received low tidal volume ventilation.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of pulmonary complications within the first 5 postoperative days, including severe respiratory failure, bronchospasm, suspected pulmonary infection, pulmonary infiltrates, aspiration pneumonitis, atelectasis, acute respiratory distress syndrome, pleural effusion, cardiopulmonary edema, and pneumothorax. Among the 16 prespecified secondary outcomes, 4 concerned intraoperative complications, including hypotension (decrease in mean arterial pressure of >20% for >3 minutes) and desaturation (Spo2 <92% for >1 minute).

RESULTS: Among 1468 adults, 1435 (98%) completed the trial (median [IQR] age, 66 [57-74] years; 52% female). In the primary analysis population, the primary outcome occurred in 142 of 718 patients (19.8%) in the driving pressure-guided high PEEP group compared with 125 of 717 patients (17.4%) in the low PEEP group (absolute difference, 2.5% [95% CI, -1.5% to 6.4%]; P = .23). The incidence of hypotension (382 [54.0%] vs 317 [45.0%]) and use of vasoactive agents (224 [32.0%] vs 130 [18.8%]) was higher in the high PEEP group; the incidence of intraoperative desaturation (6 [0.8%] vs 20 [2.8%]) was higher in the low PEEP group.

CONCLUSIONS AND RELEVANCE: Among patients at increased risk for postoperative pulmonary complications undergoing open abdominal surgery under general anesthesia, intraoperative ventilation with driving pressure-guided high PEEP and recruitment maneuvers, compared with a strategy with standard low PEEP, did not reduce postoperative pulmonary complications.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03884543.

**中文摘要译文：**
重要性：针对低驱动压的个体化高呼气末正压（PEEP）和肺复张策略对接受开腹手术患者临床结局的影响尚不确定。

目的：比较驱动压引导的高PEEP联合肺复张策略与标准低PEEP不联合肺复张策略在术后肺部并发症方面的差异。

设计、设置和参与者：这是一项针对1435名术后肺部并发症风险增加的成年患者的随机临床试验，这些患者计划接受开腹手术。该试验于2019年4月至2024年12月期间在欧洲5个国家的29个中心进行；最终随访于2025年3月完成。统计分析于2025年5月进行。

干预措施：患者被随机分配接受术中通气，采用驱动压引导的高PEEP联合肺复张策略（n=718），或接受术中通气，采用标准低PEEP（n=717）。所有患者均接受低潮气量通气。

主要结局指标：主要结局是术后前5天内肺部并发症的复合终点，包括严重呼吸衰竭、支气管痉挛、疑似肺部感染、肺部浸润、吸入性肺炎、肺不张、急性呼吸窘迫综合征、胸腔积液、心肺水肿和气胸。在16个预设的次要结局中，有4个涉及术中并发症，包括低血压（平均动脉压下降>20%持续>3分钟）和氧饱和度下降（SpO2<92%持续>1分钟）。

结果：在1468名成年患者中，1435名（98%）完成了试验（中位[IQR]年龄为66[57-74]岁；52%为女性）。在主要分析人群中，驱动压引导的高PEEP组718名患者中有142名（19.8%）发生了主要结局，而低PEEP组717名患者中有125名（17.4%）发生了主要结局（绝对差异为2.5%[95% CI，-1.5%至6.4%]；P=0.23）。高PEEP组低血压发生率（382[54.0%]对比317[45.0%]）和血管活性药物使用率（224[32.0%]对比130[18.8%]）更高；低PEEP组术中氧饱和度下降发生率更高（6[0.8%]对比20[2.8%]）。

结论和相关性：在接受全身麻醉下开腹手术且术后肺部并发症风险增加的患者中，与标准低PEEP策略相比，采用驱动压引导的高PEEP联合肺复张策略的术中通气并未减少术后肺部并发症。

试验注册：ClinicalTrials.gov标识符：NCT03884543。

### 第二部分 AI 大师评价

本研究旨在探讨驱动压引导的高PEEP联合肺复张策略对开腹手术患者术后肺部并发症的预防效果。通过一项多中心随机临床试验，研究者比较了该个体化通气策略与标准低PEEP策略的临床差异。关键发现显示，尽管高PEEP策略在氧合方面略有优势，但未能显著降低术后肺部并发症发生率，反而增加了低血压和血管活性药物使用的风险。这项研究具有重要的临床价值，它挑战了传统认为高PEEP策略必然有益的假设，提示在开腹手术中过度追求低驱动压可能带来血流动力学不稳定等新问题，为围术期通气策略的个体化选择提供了重要循证依据。

---

## 2. 动脉瘤性蛛网膜下腔出血后的脑脊液分流：迈向个体化治疗策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331820](https://pubmed.ncbi.nlm.nih.gov/41331820)
**期刊：** Critical care (London, England)
**PMID：** 41331820
**DOI：** 10.1186/s13054-025-05788-8

### 第一部分 原文与翻译

**英文原标题：** CSF diversion after aneurysmal sub-arachnoid hemorrhage: towards personalized treatment strategies.

**英文摘要原文：**
Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening condition associated with high morbidity and mortality, with survivors often experiencing long-term neurological and functional deficits. Cerebrospinal fluid (CSF) diversion plays a pivotal role in the acute management of aSAH, both for the treatment of hydrocephalus and for the prevention of delayed cerebral ischemia (DCI) through clearance of blood breakdown products. Four principal modalities are currently employed: lumbar puncture, lumbar, cisternal, and external ventricular drain. Each technique differs in its mechanism of drainage, monitoring capacity, complication profile, and influence on shunt dependency and long-term outcome. High-quality evidence from randomized controlled trials now supports lumbar drainage as the only intervention that significantly reduces the incidence of DCI and has been shown to improve functional outcomes, making it the preferred first-line approach in suitable patients. External ventricular drains remain indispensable in cases of obstructive hydrocephalus or reduced consciousness, while lumbar puncture may be considered in carefully selected low-risk patients. Cisternal drains represent a potential adjunct in those undergoing surgical clipping of the aneurysm. In patients without hydrocephalus, lumbar drains remain the only strategy with demonstrated long-term benefit. Given the heterogeneity of aSAH presentations and the limitations of existing evidence, individualized selection of CSF diversion techniques is warranted. We propose a pragmatic decision-making algorithm to optimize patient outcomes while minimizing iatrogenic complications, which can be adapted to institutional practices and further refined through prospective evaluation.

**中文摘要译文：**
动脉瘤性蛛网膜下腔出血（aSAH）是一种危及生命的疾病，具有高发病率和死亡率，幸存者常经历长期的神经功能和功能缺陷。脑脊液（CSF）分流在aSAH的急性管理中起着关键作用，既用于治疗脑积水，又通过清除血液分解产物来预防迟发性脑缺血（DCI）。目前主要采用四种方式：腰椎穿刺、腰椎引流、脑池引流和脑室外引流。每种技术在引流机制、监测能力、并发症特征以及对分流依赖性和长期结局的影响方面各不相同。来自随机对照试验的高质量证据现在支持腰椎引流作为唯一能显著降低DCI发生率并已被证明能改善功能结局的干预措施，使其成为适合患者的首选一线方法。脑室外引流在梗阻性脑积水或意识水平降低的情况下仍然不可或缺，而腰椎穿刺可在精心选择的低风险患者中考虑使用。脑池引流可作为接受动脉瘤手术夹闭患者的潜在辅助手段。在无脑积水患者中，腰椎引流仍然是唯一具有明确长期获益的策略。鉴于aSAH临床表现的异质性和现有证据的局限性，有必要个体化选择脑脊液分流技术。我们提出一个实用的决策算法，以优化患者结局，同时最大限度地减少医源性并发症，该算法可根据机构实践进行调整，并通过前瞻性评估进一步完善。

### 第二部分 AI 大师评价

本研究旨在系统评价动脉瘤性蛛网膜下腔出血后脑脊液分流的不同技术，并基于现有证据提出个体化治疗策略。通过综合分析四种主要分流方式（腰椎穿刺、腰椎引流、脑池引流和脑室外引流）的特点、适应症和临床证据，研究明确指出腰椎引流是唯一能显著降低迟发性脑缺血发生率并改善功能结局的干预措施，应作为适合患者的首选一线方法。该研究的创新性在于整合了高质量随机对照试验证据，提出了实用的临床决策算法，为个体化治疗提供了循证依据，具有重要的临床指导价值。然而，研究也承认现有证据的局限性，强调需要根据患者具体情况进行个体化选择，并建议通过前瞻性评估进一步完善治疗策略。

---

## 3. 系统性超声引导下中心静脉置管的部位特异性并发症：一项重新审视3SITES研究的目标试验仿真研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331661](https://pubmed.ncbi.nlm.nih.gov/41331661)
**期刊：** Critical care (London, England)
**PMID：** 41331661
**DOI：** 10.1186/s13054-025-05747-3

### 第一部分 原文与翻译

**英文原标题：** Site-specific complications of central venous catheterization under systematic ultrasound guidance: a target trial emulation revisiting the 3SITES study.

**英文摘要原文：**
BACKGROUND: Central venous catheterization is the most common invasive procedure in intensive care units but remains burdened by infectious, thrombotic, and mechanical complications. Although real-time ultrasound guidance is now widely adopted, its effect on site-specific differences in overall complication rates has not been established. The 3SITES randomized clinical trial previously demonstrated lower infection and thrombosis rates with subclavian access but higher mechanical complications. However, as only a third of its procedures were ultrasound-guided in this study, these findings may not apply to current practice. The objective of the study was to compare complication rates across these three sites under a counterfactual framework assuming universal ultrasound guidance.

METHODS: This study was an emulated a target trial using the 3SITES dataset. Inverse probability weighting was applied to adjust for confounders of site assignment and ultrasound guidance. Weighted outcomes across catheter sites were compared under a counterfactual framework assuming universal ultrasound guidance. The primary outcome was a composite of time to catheter-related bloodstream infection or symptomatic deep-vein thrombosis. Secondary outcomes included each component separately, asymptomatic thrombosis, and major mechanical complications.

RESULTS: A total of 3409 catheters were included: 1153 in the femoral, 1267 in the internal jugular, and 989 in the subclavian site. Subclavian site showed a lower incidence of the primary outcome compared with femoral (P = .02) and jugular (P = .001) sites. The primary composite outcome did not differ between internal jugular and femoral sites (P = .97). Catheter-related bloodstream infections were significantly fewer with subclavian versus jugular access (P = .001). Asymptomatic thrombosis was more frequent at femoral and jugular sites. Major mechanical complications were rare and did not differ significantly across sites.

CONCLUSION: Assuming universal real-time ultrasound-guided central venous catheterization, subclavian access retains lower infectious and thrombotic risk without an observed increase in mechanical complications, supporting its preferential use in intensive care units.

**中文摘要译文：**
背景：中心静脉置管是重症监护病房中最常见的侵入性操作，但仍存在感染性、血栓性和机械性并发症的负担。尽管实时超声引导现已广泛采用，但其对不同部位总体并发症率差异的影响尚未确定。3SITES随机临床试验先前已证明锁骨下入路具有较低的感染和血栓发生率，但机械性并发症较高。然而，由于该研究中仅有三分之一的操作采用了超声引导，这些发现可能不适用于当前实践。本研究的目标是在假设普遍采用超声引导的反事实框架下，比较这三个部位的并发症率。

方法：本研究使用3SITES数据集仿真了一个目标试验。应用逆概率加权来调整部位选择和超声引导的混杂因素。在假设普遍采用超声引导的反事实框架下，比较了不同导管部位的加权结果。主要结局是导管相关血流感染或有症状深静脉血栓形成的时间复合终点。次要结局包括各组成部分单独分析、无症状血栓形成和主要机械性并发症。

结果：共纳入3409根导管：股静脉1153根，颈内静脉1267根，锁骨下静脉989根。与股静脉（P=0.02）和颈内静脉（P=0.001）相比，锁骨下部位显示出较低的主要结局发生率。颈内静脉和股静脉之间的主要复合结局无差异（P=0.97）。锁骨下入路与颈内静脉入路相比，导管相关血流感染显著减少（P=0.001）。无症状血栓形成在股静脉和颈内静脉部位更为常见。主要机械性并发症罕见，且在不同部位间无显著差异。

结论：假设普遍采用实时超声引导的中心静脉置管，锁骨下入路仍保持较低的感染和血栓风险，且未观察到机械性并发症增加，支持其在重症监护病房中的优先使用。

### 第二部分 AI 大师评价

本研究通过目标试验仿真方法，在反事实框架下重新评估了不同中心静脉置管部位在普遍超声引导下的并发症差异。研究创新性地利用3SITES试验原始数据，采用逆概率加权调整混杂因素，模拟了当前超声引导广泛应用的临床场景。关键发现表明，在超声引导普遍化背景下，锁骨下入路仍保持较低的感染和血栓风险优势，且未增加机械性并发症，这为临床实践中优先选择锁骨下入路提供了有力证据。研究的局限性在于其仿真性质，虽然通过统计方法模拟了普遍超声引导场景，但仍需前瞻性随机对照试验进一步验证；尽管如此，本研究为优化中心静脉置管策略提供了重要的循证依据，具有显著的临床指导价值。

---

## 4. 缺氧后昏迷患者持续脑电图监测的效用：一项回顾性多中心研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331652](https://pubmed.ncbi.nlm.nih.gov/41331652)
**期刊：** Critical care (London, England)
**PMID：** 41331652
**DOI：** 10.1186/s13054-025-05773-1

### 第一部分 原文与翻译

**英文原标题：** Utility of continuous EEG monitoring in postanoxic coma: a retrospective multicenter study.

**英文摘要原文：**
BACKGROUND: Following postanoxic coma, continuous electroencephalography (cEEG) monitoring is widely applied for prognostication, guided by national guidelines recommending multimodal assessment. While the diagnostic accuracy of cEEG is well-established, its actual outcomes and impact on intensive care unit (ICU) length of stay (LOS) have largely remained unreported since guideline implementation. This study evaluates outcomes and the unique prognostic value of cEEG monitoring in patients with postanoxic coma after guideline implementation.

METHODS: This retrospective multicenter study analyzed 699 patients with postanoxic coma who underwent cEEG monitoring between January 2021 and January 2024 across three Dutch academic centers. Prognostic outcomes (favorable, poor, or uncertain) were classified based on established EEG patterns at 12- and 24-hour timepoints. For patients with a poor cEEG prognosis, clinical indicators (neurological examination, hemodynamic stability, additional prognostic modalities) were assessed to determine cEEG's unique contribution.

RESULTS: Of 699 patients, 13.0% (n = 91) had a favorable, 16.2% (n = 113) a poor, and 70.8% (n = 495) an uncertain prognosis. Among those with a poor cEEG prognosis, 58% also had clinical indicators of a poor prognosis such as wide pupils with absent light reflexes or hemodynamic instability. Only 6.7% (n = 47) of all cEEGs provided unique additional prognostic value, with no other clinical indicators suggesting a poor prognosis.

CONCLUSIONS: cEEG monitoring provided unique prognostic information in a small percentage of cases, with most yielding uncertain prognoses. This suggests current universal cEEG monitoring may be suboptimal given resource constraints and limited additional diagnostic yield.

**中文摘要译文：**
背景：在缺氧后昏迷患者中，持续脑电图（cEEG）监测被广泛应用于预后评估，这遵循了推荐多模态评估的国家指南。虽然cEEG的诊断准确性已得到充分证实，但自指南实施以来，其实际结果和对重症监护病房（ICU）住院时间（LOS）的影响在很大程度上仍未得到报告。本研究评估了指南实施后缺氧后昏迷患者cEEG监测的结果及其独特的预后价值。

方法：这项回顾性多中心研究分析了2021年1月至2024年1月期间在荷兰三个学术中心接受cEEG监测的699名缺氧后昏迷患者。预后结果（良好、不良或不确定）基于12小时和24小时时间点的既定脑电图模式进行分类。对于cEEG预后不良的患者，评估了临床指标（神经系统检查、血流动力学稳定性、其他预后模式）以确定cEEG的独特贡献。

结果：在699名患者中，13.0%（n=91）预后良好，16.2%（n=113）预后不良，70.8%（n=495）预后不确定。在cEEG预后不良的患者中，58%同时具有临床预后不良指标，如瞳孔散大伴光反射消失或血流动力学不稳定。在所有cEEG监测中，仅有6.7%（n=47）提供了独特的额外预后价值，且没有其他临床指标提示预后不良。

结论：cEEG监测仅在少数病例中提供了独特的预后信息，大多数情况下产生不确定的预后结果。这表明考虑到资源限制和有限的额外诊断收益，当前普遍应用的cEEG监测可能并非最优选择。

### 第二部分 AI 大师评价

本研究通过回顾性多中心设计，系统评估了指南实施后持续脑电图（cEEG）监测在缺氧后昏迷患者中的实际临床效用。研究创新性地量化了cEEG的'独特预后价值'，发现仅有6.7%的监测提供了超出常规临床评估的额外信息，而高达70.8%的病例预后仍不确定。这一发现具有重要临床意义，提示在当前医疗资源有限的情况下，普遍应用cEEG监测的策略可能需要重新评估和优化。研究的局限性在于其回顾性设计，未来需要前瞻性研究进一步验证这些发现，并探索更精准的cEEG应用指征。

---

## 5. β-内酰胺类药物在急性肾损伤危重患者中的剂量调整：一项范围综述

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331481](https://pubmed.ncbi.nlm.nih.gov/41331481)
**期刊：** Critical care (London, England)
**PMID：** 41331481
**DOI：** 10.1186/s13054-025-05736-6

### 第一部分 原文与翻译

**英文原标题：** Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review.

**英文摘要原文：**
BACKGROUND: Acute kidney injury is a common complication in critically ill patients, often coinciding with the need for antibiotic therapy. The dose of beta-lactam antibiotics is frequently adjusted and often reduced based on estimated Glomerular Filtration Rate. However, early dose reductions may lead to underdosing, especially during the critical first 48 h of infection treatment, when acute kidney injury may be transient and adequate antibiotic treatment is critical. While some reviews suggest delaying dose reductions improves clinical outcomes, evidence remains limited. This scoping review evaluates the current literature on beta-lactam dosing strategies in critically ill patients with acute kidney injury, focusing on pharmacological and clinical outcomes.

METHODS: We conducted a systematic scoping review following PRISMA-ScR guidelines. We searched Medline, Embase, Web of Science, Cochrane CENTRAL, and Google Scholar from database inception through March 24, 2025. Two reviewers independently screened all articles and assessed study quality using ROB-2 and ROBINS-E tools. Eligible studies included critically ill adult patients with acute kidney injury, receiving beta-lactams, and reporting clinical or pharmacological outcomes. Data were extracted using a standardized template and categorized by pharmacological or clinical outcomes. Further stratification by antibiotic type or patient characteristics was not feasible.

RESULTS: Out of the 1,436 screened articles, 11 studies involving 1,407 patients were included. The risk of bias was high in most studies. Most studies were observational; one was a randomized controlled trial. Seven studies reported beta-lactam plasma concentrations. Higher concentrations were generally observed in patients with acute kidney injury, even though dosages were oftentimes already reduced. One study associated early dose reductions with lower rates of neurotoxicity. One study reported higher rates of treatment failure with early dose reductions and three studies linked delayed dose reductions to reduced mortality.

CONCLUSIONS: Current evidence on beta-lactam dose reduction in critically ill patients with acute kidney injury is limited and of low quality. Delaying reductions may improve clinical outcomes, but further prospective studies are urgently needed.

TRIAL REGISTRATION: The protocol for this scoping review was not prospectively registered.

**中文摘要译文：**
背景：急性肾损伤是危重患者的常见并发症，常与需要抗生素治疗同时发生。β-内酰胺类抗生素的剂量常根据估算的肾小球滤过率进行调整，且常被减量。然而，早期剂量减量可能导致剂量不足，尤其是在感染治疗的关键前48小时内，此时急性肾损伤可能是暂时性的，而充分的抗生素治疗至关重要。尽管一些综述建议延迟剂量减量可改善临床结局，但证据仍然有限。本范围综述评估了当前关于急性肾损伤危重患者中β-内酰胺类药物给药策略的文献，重点关注药理学和临床结局。

方法：我们按照PRISMA-ScR指南进行了系统性范围综述。我们检索了Medline、Embase、Web of Science、Cochrane CENTRAL和Google Scholar数据库，检索时间从数据库建立至2025年3月24日。两名评审员独立筛选所有文章，并使用ROB-2和ROBINS-E工具评估研究质量。符合条件的研究包括接受β-内酰胺类药物治疗并报告临床或药理学结局的急性肾损伤危重成年患者。使用标准化模板提取数据，并按药理学或临床结局进行分类。按抗生素类型或患者特征进一步分层不可行。

结果：在筛选的1,436篇文章中，纳入了11项研究，涉及1,407名患者。大多数研究的偏倚风险较高。大多数研究为观察性研究；其中一项为随机对照试验。七项研究报告了β-内酰胺类药物的血浆浓度。即使在剂量通常已经减量的情况下，急性肾损伤患者中通常观察到较高的药物浓度。一项研究将早期剂量减量与较低的神经毒性发生率相关联。一项研究报告早期剂量减量与较高的治疗失败率相关，三项研究将延迟剂量减量与降低的死亡率相关联。

结论：目前关于急性肾损伤危重患者中β-内酰胺类药物剂量减量的证据有限且质量较低。延迟减量可能改善临床结局，但迫切需要进一步的前瞻性研究。

试验注册：本范围综述的方案未进行前瞻性注册。

### 第二部分 AI 大师评价

本研究通过系统性范围综述，深入探讨了急性肾损伤危重患者中β-内酰胺类抗生素剂量调整策略的现有证据。研究采用PRISMA-ScR指南，系统检索了多个数据库，纳入了11项研究共1,407名患者，方法学严谨。核心发现表明，尽管急性肾损伤患者常接受剂量减量，但仍可能达到较高的血药浓度，且延迟剂量减量可能与改善临床结局（如降低死亡率）相关。该研究的创新性在于首次系统梳理了这一临床实践中常见但证据有限的问题，具有重要的临床指导价值，但受限于现有研究的偏倚风险高和证据质量低，仍需高质量前瞻性研究进一步验证。

---

## 6. 辅助性噬菌体疗法实现慢性免疫性皮肤疾病化脓性汗腺炎的长期疾病缓解

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41331246](https://pubmed.ncbi.nlm.nih.gov/41331246)
**期刊：** Nature communications
**PMID：** 41331246
**DOI：** 10.1038/s41467-025-65939-x

### 第一部分 原文与翻译

**英文原标题：** Prolonged disease remission of the chronic immunological skin disorder hidradenitis suppurativa with adjunctive bacteriophage therapy.

**英文摘要原文：**
Hidradenitis suppurativa (HS) is a chronic skin disease in which the acute development of noduli, abscesses and in a later stage fistulas remains difficult to control, despite a wide range of recommended treatment options including immunomodulatory biologicals, surgical intervention and antibiotics. Besides being painful, associated lesions have an extensive impact on the quality of life. While HS is primarily an immune-mediated inflammatory disease, the skin microbiota plays a key role in its pathogenesis with pathogenic bacterial colonization of lesions observed. Bacteriophages, the viruses of bacteria, are used to treat a 52-year-old female HS patient with re-current colonization of lesions with Staphylococcus aureus. Phage therapy results in complete removal of lesions with a flare-free period of six months, along with a substantial improvement in the patient's quality of life. The deployed experimental framework and the gained clinical experience will be valuable for future HS phage therapy research.

**中文摘要译文：**
化脓性汗腺炎（HS）是一种慢性皮肤疾病，尽管有多种推荐治疗方案，包括免疫调节生物制剂、手术干预和抗生素，但其急性期出现的结节、脓肿以及后期形成的瘘管仍难以控制。除了疼痛外，相关皮损对患者生活质量产生广泛影响。虽然HS主要是一种免疫介导的炎症性疾病，但皮肤微生物群在其发病机制中起着关键作用，已观察到病变部位存在致病菌定植。噬菌体（细菌的病毒）被用于治疗一名52岁女性HS患者，该患者病变部位反复出现金黄色葡萄球菌定植。噬菌体疗法实现了病灶的完全清除，患者获得了六个月的无复发期，同时生活质量得到显著改善。所部署的实验框架和获得的临床经验将对未来HS噬菌体疗法的研究具有重要价值。

### 第二部分 AI 大师评价

本研究旨在探索噬菌体疗法作为辅助治疗手段对难治性慢性皮肤疾病化脓性汗腺炎的疗效。研究采用噬菌体靶向治疗一名52岁女性HS患者的金黄色葡萄球菌感染，方法具有特异性强、副作用小的特点。关键发现显示噬菌体治疗实现了病灶完全清除和长达6个月的无复发期，显著改善了患者生活质量。创新性在于将噬菌体疗法应用于HS这一传统治疗效果有限的免疫性皮肤疾病，为临床治疗提供了新思路。临床价值在于为对常规治疗反应不佳的患者提供了替代方案，科研价值在于建立了HS噬菌体治疗的研究框架。局限性为单病例研究，需要更大规模的临床试验验证疗效和安全性，潜在影响可能推动噬菌体疗法在更多皮肤感染性疾病中的应用。

---

## 7. 涉及噬菌体编码DNA结合蛋白和细菌逆转录酶DRT4的抗噬菌体防御机制

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41330908](https://pubmed.ncbi.nlm.nih.gov/41330908)
**期刊：** Nature communications
**PMID：** 41330908
**DOI：** 10.1038/s41467-025-66997-x

### 第一部分 原文与翻译

**英文原标题：** Anti-phage defense mechanism involving phage-encoded DNA binding protein and bacterial reverse transcriptase DRT4.

**英文摘要原文：**
Prokaryotic defense-associated reverse transcriptase (DRT) systems confer host resistance to viral infection through DNA synthesis; however, the molecular mechanisms underlying their function remain poorly understood. Here, we demonstrate that DRT4, a single-gene anti-phage defense system, synthesizes single-stranded DNA (ssDNA) products of random sequences in a template-independent manner. High-resolution cryo-EM structures of DRT4 in multiple functional states elucidate its oligomeric architecture, catalytic metal ion coordination, and substrate/DNA product binding, offering mechanistic insights into its promiscuous polymerization activity. Structural and biochemical analyses further identify a conserved tyrosine residue that acts as the priming site for the initiation of DNA synthesis. Upon phage infection, a phage-encoded DNA-binding protein, ORF55, protects the 3' end of the DRT4-synthesized ssDNA from host exonuclease degradation, likely resulting in toxic ssDNA accumulation that leads to cell death. Remarkably, ORF55 also activates DRT6, a structural homolog of DRT4, suggesting a conserved activation mechanism among related DRT systems. These findings provide structural and mechanistic insights into DRT4-mediated antiviral defense, establishing a distinct paradigm for antiviral reverse transcriptase in bacterial immunity.

**中文摘要译文：**
原核生物防御相关逆转录酶（DRT）系统通过DNA合成赋予宿主对病毒感染的抵抗力；然而，其功能背后的分子机制仍知之甚少。本文中，我们证明DRT4这一单基因抗噬菌体防御系统以不依赖模板的方式合成随机序列的单链DNA（ssDNA）产物。DRT4在多种功能状态下的高分辨率冷冻电镜结构阐明了其寡聚体结构、催化金属离子配位以及底物/DNA产物结合，为其混杂聚合活性提供了机制性见解。结构和生化分析进一步鉴定出一个保守的酪氨酸残基，该残基作为DNA合成起始的引物位点。在噬菌体感染时，噬菌体编码的DNA结合蛋白ORF55保护DRT4合成的ssDNA的3'末端免受宿主外切核酸酶降解，可能导致毒性ssDNA积累从而引起细胞死亡。值得注意的是，ORF55还能激活DRT4的结构同源物DRT6，提示相关DRT系统之间存在保守的激活机制。这些发现为DRT4介导的抗病毒防御提供了结构和机制性见解，为细菌免疫中的抗病毒逆转录酶建立了一个独特的范式。

### 第二部分 AI 大师评价

本研究旨在阐明细菌抗噬菌体防御系统DRT4的分子机制。研究团队采用高分辨率冷冻电镜结构解析结合生化分析的方法，揭示了DRT4以不依赖模板的方式合成随机序列单链DNA的独特机制。关键发现包括：鉴定出保守酪氨酸残基作为DNA合成起始位点，发现噬菌体编码蛋白ORF55通过保护ssDNA 3'末端激活防御系统，并证实该激活机制在相关DRT系统中具有保守性。这项研究的创新性在于首次系统揭示了DRT4的结构与功能机制，建立了细菌抗病毒逆转录酶的新范式，为理解原核生物免疫系统进化提供了重要见解，对开发新型抗病毒策略和噬菌体疗法具有潜在价值。研究主要基于体外实验，未来需要在活体细菌系统中进一步验证这些机制。

---

## 8. ARDS与脓毒症炎症表型的纵向多组学特征揭示与死亡率相关的通路

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329523](https://pubmed.ncbi.nlm.nih.gov/41329523)
**期刊：** The Journal of clinical investigation
**PMID：** 41329523
**DOI：** 10.1172/JCI196290

### 第一部分 原文与翻译

**英文原标题：** Longitudinal multi-omic signatures of ARDS and sepsis inflammatory phenotypes identify pathways associated with mortality.

**英文摘要原文：**
BACKGROUND: Critically ill patients with acute respiratory distress syndrome (ARDS) and sepsis exhibit distinct inflammatory phenotypes with divergent clinical outcomes, but the underlying molecular mechanisms remain poorly understood. These phenotypes, derived from clinical data and protein biomarkers, were associated with metabolic differences in a pilot study.

METHODS: We performed integrative multi-omics analysis of blood samples from 160 ARDS patients in the ROSE trial, randomly selecting 80 patients from each latent class analysis-defined inflammatory phenotype (Hyperinflammatory and Hypoinflammatory) with phenotype probability >0.9. Untargeted plasma metabolomics and whole blood transcriptomics at Day 0 and Day 2 were analyzed using multi-modal factor analysis (MEFISTO). The primary outcome was 90-day mortality, with validation in an independent critically ill sepsis cohort (EARLI).

RESULTS: Multi-omics integration revealed four molecular signatures associated with mortality: (1) enhanced innate immune activation coupled with increased glycolysis (associated with Hyperinflammatory phenotype), (2) hepatic dysfunction and immune dysfunction paired with impaired fatty acid beta-oxidation (associated with Hyperinflammatory phenotype), (3) interferon program suppression coupled with altered mitochondrial respiration (associated with Hyperinflammatory phenotype), and (4) redox impairment and cell proliferation pathways (not associated with inflammatory phenotype). These signatures persisted through Day 2 of trial enrollment. Within-phenotype analysis revealed distinct mortality-associated pathways in each group. All molecular signatures were validated in the independent EARLI cohort.

CONCLUSIONS: Inflammatory phenotypes of ARDS reflect distinct underlying biological processes with both phenotype-specific and phenotype-independent pathways influencing patient outcomes, all characterized by mitochondrial dysfunction. These findings suggest potential therapeutic targets for precise treatment strategies in critical illness.

FUNDING: This work is the result of NIH funding.

**中文摘要译文：**
背景：急性呼吸窘迫综合征（ARDS）和脓毒症的危重患者表现出不同的炎症表型，具有不同的临床结局，但其潜在的分子机制仍知之甚少。这些基于临床数据和蛋白质生物标志物推导的表型，在一项初步研究中与代谢差异相关。

方法：我们对ROSE试验中160名ARDS患者的血液样本进行了整合多组学分析，从潜在类别分析定义的炎症表型（高炎症型和低炎症型）中各随机选择80名表型概率>0.9的患者。使用多模态因子分析（MEFISTO）分析了第0天和第2天的非靶向血浆代谢组学和全血转录组学数据。主要结局是90天死亡率，并在独立的危重脓毒症队列（EARLI）中进行了验证。

结果：多组学整合揭示了四种与死亡率相关的分子特征：（1）增强的先天免疫激活伴随糖酵解增加（与高炎症表型相关），（2）肝功能不全和免疫功能失调伴随脂肪酸β-氧化受损（与高炎症表型相关），（3）干扰素程序抑制伴随线粒体呼吸改变（与高炎症表型相关），以及（4）氧化还原损伤和细胞增殖通路（与炎症表型无关）。这些特征在试验入组第2天持续存在。表型内分析揭示了每组中不同的死亡率相关通路。所有分子特征均在独立的EARLI队列中得到验证。

结论：ARDS的炎症表型反映了不同的潜在生物学过程，既有表型特异性通路，也有表型非依赖性通路影响患者结局，所有这些特征均以线粒体功能障碍为特点。这些发现提示了危重疾病精准治疗策略的潜在治疗靶点。

资助：本研究由美国国立卫生研究院（NIH）资助。

### 第二部分 AI 大师评价

本研究通过整合多组学方法，深入探究了ARDS和脓毒症不同炎症表型背后的分子机制及其与死亡率的关系。研究采用纵向设计，结合代谢组学和转录组学数据，并运用多模态因子分析技术，系统识别出四种与死亡率相关的分子特征。创新性地揭示了线粒体功能障碍是不同表型的共同病理基础，同时发现了表型特异性和非特异性的死亡相关通路。该研究不仅为理解危重疾病异质性提供了重要的分子见解，也为开发精准治疗策略指明了潜在靶点，具有重要的临床转化价值。然而，研究仍需在更大样本和更广泛的疾病谱中进行验证，以评估其普适性。

---

## 9. CARD9依赖性巨噬细胞可塑性调控真菌有效清除

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41329515](https://pubmed.ncbi.nlm.nih.gov/41329515)
**期刊：** The Journal of clinical investigation
**PMID：** 41329515
**DOI：** 10.1172/JCI188827

### 第一部分 原文与翻译

**英文原标题：** CARD9-dependent macrophage plasticity regulates effective fungal clearance.

**英文摘要原文：**
The role of CARD9 in the pathogenesis of various chronic fungal infections has been established; however, the precise mechanisms underlying the pathobiology of these infections remain unclear. We aimed to investigate the specific cellular mechanisms by which CARD9 deficiency contributes to the pathogenesis of chronic fungal infections. Using single-cell RNA sequencing (scRNA-seq), we analyzed the immune cell profiles in skin lesions from both murine and human samples. We focused on macrophage differentiation and signaling pathways influenced by CARD9 deficiency. We found that CARD9 deficiency promotes the differentiation of TREM2high macrophages following fungal stimulation, impairing their antifungal functions and inducing exhaustion-like T helper 1 (Th1) cells. Mechanistically, the NF-κB pathway activation was restricted in CARD9-deficient macrophages, leading to enhanced CREB activation, which in turn exerted a positive regulatory effect on Trem2 expression by activating C/EBPβ. Notably, targeting TREM2 enhanced the antifungal immune response in vivo and in vitro, thereby alleviating the severity of CARD9-deficient subcutaneous dematiaceous fungal infection. Our findings highlight the important role of CARD9 in regulating cutaneous antifungal immunity and identify potential targets for immunotherapy in chronic dematiaceous fungal infections.

**中文摘要译文：**
CARD9在各种慢性真菌感染的发病机制中的作用已被确立；然而，这些感染病理生物学的确切机制仍不清楚。我们旨在研究CARD9缺陷导致慢性真菌感染发病机制的具体细胞机制。使用单细胞RNA测序（scRNA-seq），我们分析了小鼠和人类样本皮肤病变中的免疫细胞谱。我们重点关注受CARD9缺陷影响的巨噬细胞分化和信号通路。我们发现，CARD9缺陷在真菌刺激后促进TREM2高表达巨噬细胞的分化，损害其抗真菌功能并诱导耗竭样T辅助1（Th1）细胞。从机制上讲，CARD9缺陷巨噬细胞中NF-κB通路激活受限，导致CREB激活增强，进而通过激活C/EBPβ对Trem2表达产生正向调节作用。值得注意的是，靶向TREM2在体内和体外均增强了抗真菌免疫反应，从而减轻了CARD9缺陷型皮下暗色丝孢霉真菌感染的严重程度。我们的研究结果突显了CARD9在调节皮肤抗真菌免疫中的重要作用，并确定了慢性暗色丝孢霉真菌感染免疫治疗的潜在靶点。

### 第二部分 AI 大师评价

本研究旨在阐明CARD9缺陷导致慢性真菌感染的具体细胞机制，采用单细胞RNA测序技术分析小鼠和人类皮肤病变的免疫细胞谱。研究发现CARD9缺陷通过限制NF-κB通路、增强CREB激活，进而上调TREM2表达，促进功能受损的TREM2高表达巨噬细胞分化。该研究的创新性在于揭示了CARD9-TREM2轴在真菌免疫中的调控作用，并证明靶向TREM2可增强抗真菌反应，为慢性暗色丝孢霉真菌感染提供了新的免疫治疗靶点。虽然研究在机制上取得了重要突破，但未来仍需在更广泛的真菌感染模型中验证这一通路的普适性，并探索TREM2靶向治疗的具体临床应用策略。

---

速递结束，祝您工作愉快！